Dan J. Mogren appointed as permanent CEO of Clinical Laserthermia Systems
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announced that the Board of Directors has appointed Dan J. Mogren as permanent CEO of CLS. Dan J. Mogren has been acting CEO since December 1, 2020.
– Dan has done an excellent job as acting CEO and demonstrated both leadership skills and a deep understanding of CLS and how to execute on the strategy in order to reach our goals. I am very pleased that Dan will continue as permanent CEO to drive the company forward as we prepare the company for a full market launch, says Hans von Celsing, Chairman of the Board, CLS.
– I’m excited to be the permanent CEO of CLS and continue to develop the company in line with our strategic focus on providing the right product offering, generate requested clinical evidence and increasing the pace of commercialization within our prioritized market segments, says Dan J. Mogren, CEO of CLS.
Dan J. Mogren has been acting CEO of CLS since December 1, 2020. Before that he was Chief Commercial Officer at CLS 2009-2020. In total, he has 30 years’ experience from management positions in business and product development, marketing and sales, and more than 25 years’ experience of international marketing of medtech products. Dan J. Mogren has founded and developed several companies in different medtech areas.
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out below.
Contact Information:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 – (0)705 – 90 11 40 E-mail: dan.mogren@clinicallaser.com
About CLS and TRANBERG system
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®,
the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-05-2022 08:30 CET.